Drug Type Biological products |
Synonyms TSO, CNDO-201, TSO 2500 + [1] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autism Spectrum Disorder | Phase 2 | US | 01 May 2014 | |
Autistic Disorder | Phase 2 | US | 01 May 2014 | |
Plaque psoriasis | Phase 2 | - | 01 Mar 2014 | |
Psoriasis | Phase 2 | - | 01 Mar 2014 | |
Colitis, Ulcerative | Phase 2 | US | 01 Nov 2013 | |
Crohn Disease | Phase 2 | US | 01 Jul 2012 | |
Multiple Sclerosis | Phase 2 | DK | - | |
Multiple Sclerosis | Phase 2 | - | - | |
Rheumatoid Arthritis | Phase 2 | DE | - | |
Rheumatoid Arthritis | Phase 2 | - | - |
Phase 2 | 250 | Placebo (Placebo) | mbhfzifxed(uyhexeuzlo) = drskwggdcg pskvanwxqw (qajahlwpzq, uanpbngkpr - ufmihqdugy) View more | - | 29 Jun 2017 | ||
(TSO 7500) | mbhfzifxed(uyhexeuzlo) = ghkaihqayz pskvanwxqw (qajahlwpzq, odvyiscghy - mfqhzjapzt) View more | ||||||
Phase 1 | 36 | Placebo (Placebo) | uhhxsmcrfn(psrmtkkdjk) = rybrxfdhfj jrpqmcuhyt (gtzhccrrfj, lbqcewbczl - qnflfxjefv) View more | - | 20 May 2013 | ||
(TSO 500) | uhhxsmcrfn(psrmtkkdjk) = bforbifofu jrpqmcuhyt (gtzhccrrfj, vodhyilzrb - ebnzykucda) View more |